All In Biotech

Free tool

FAERS Monitor: Vibativ

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022110 or its brand name (Vibativ, Telavancin Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

120

Serious

91

76% of reports

Hospitalization

28

Death reported

12

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use19
  • renal failure acute15
  • blood creatinine increased12
  • nausea12
  • chills9
  • thrombocytopenia7
  • diarrhoea6
  • dyspnoea6
  • leukopenia6
  • renal failure6
  • vomiting6
  • acute kidney injury5
  • rash5
  • renal impairment5
  • tubulointerstitial nephritis5

Reports by year received

View as table
YearReports
20092
201033
201145
20125
20144
20161
201823
20194
20251
20262

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,039 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
renal failure acuteSignal1562.038.6842
tubulointerstitial nephritisSignal546.819.8181
blood creatinine increasedSignal1232.218.8333
leukopeniaSignal621.09.696
chillsSignal913.57.292
thrombocytopeniaSignal711.05.354
renal impairmentSignal510.44.434
renal failureSignal67.93.630
acute kidney injurySignal55.72.415
off label useSignal193.82.538
nauseaSignal122.71.611
vomiting62.21.03
rash52.00.92
dyspnoea61.90.92
diarrhoea61.60.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.